Cell Growth & Differentiation, Vol 6, Issue 5 579-586, Copyright © 1995 by American Association of Cancer Research

ARTICLES

12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy

DA Greenhalgh, XJ Wang, JN Eckhardt and DR Roop
Department of Cell Biology and Dermatology, Baylor College of Medicine, Houston, Texas 77030, USA.

Transgenic mice that expressed v-fos exclusively in the epidermis by means of a human keratin K1-based targeting vector (HK1.fos) developed preneoplastic epidermal hyperplasia and hyperkeratosis after long latency and an associated wound promotion stimulus. To assess the requirements for papilloma formation and malignant conversion and determine the sensitivity to a chemical promotion stimulus, HK1.fos mice were promoted with 12-O-tetradecanoylphorbol-13-acetate (TPA). HK1.fos mice were sensitive to TPA promotion but developed papillomas only after long latency (20-30 weeks of promotion) and in relatively few numbers per animal, suggesting the necessity of an additional genetic event prior to overt lesion formation. Consistent with this idea, at 60 weeks, on cessation of TPA promotion, these HK1.fos TPA-papillomas were found to be autonomous, TPA-independent tumors which persisted, grew larger, and converted to malignancy. Analysis of HK1.fos tumor RNA and DNA identified endogenous c-rasHa mutations at codons 12 and 61 in papillomas and carcinomas; however, no p53 tumor suppressor gene mutations were detected. These data indicate that epidermal expression of v-fos induces sensitivity to TPA promotion, but since additional genetic events, such as endogenous c-rasHa activation, appear to be required in tumorigenesis, v-fos may predominantly play a role in the mechanism of promotion to achieve papilloma autonomy and TPA independence. Furthermore, spontaneous malignant conversion in this model does not appear to involve mutations in the p53 tumor suppressor gene.

This article has been cited by other articles:

				D. Yao, C. L. Alexander, J. A. Quinn, W.-C. Chan, H. Wu, and D. A. Greenhalgh Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21WAF-induced differentiation triggered by GSK3{beta} inactivation and reduced AKT activity J. Cell Sci., May 15, 2008; 121(10): 1758 - 1769. [Abstract] [Full Text] [PDF]

				D. Yao, C. L. Alexander, J. A. Quinn, M. J. Porter, H. Wu, and D. A. Greenhalgh PTEN Loss Promotes rasHa-Mediated Papillomatogenesis via Dual Up-Regulation of AKT Activity and Cell Cycle Deregulation but Malignant Conversion Proceeds via PTEN-Associated Pathways Cancer Res., February 1, 2006; 66(3): 1302 - 1312. [Abstract] [Full Text] [PDF]

				K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin Carcinogenesis, May 1, 2004; 25(5): 713 - 722. [Abstract] [Full Text] [PDF]

				J. A. Curran, F. S. Laverty, D. Campbell, J. Macdiarmid, and J. B. Wilson Epstein-Barr Virus Encoded Latent Membrane Protein-1 Induces Epithelial Cell Proliferation and Sensitizes Transgenic Mice to Chemical Carcinogenesis Cancer Res., September 1, 2001; 61(18): 6730 - 6738. [Abstract] [Full Text] [PDF]

				M. R. Young, J.-J. Li, M. Rincon, R. A. Flavell, B. K. Sathyanarayana, R. Hunziker, and N. Colburn Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion PNAS, August 17, 1999; 96(17): 9827 - 9832. [Abstract] [Full Text] [PDF]

				M. Schreiber, A. Kolbus, F. Piu, A. Szabowski, U. Möhle-Steinlein, J. Tian, M. Karin, P. Angel, and E. F. Wagner Control of cell cycle progression by c-Jun is p53 dependent Genes & Dev., March 1, 1999; 13(5): 607 - 619. [Abstract] [Full Text]